Trial Profile
Severe relapses and rebound activity after natalizumab discontinuation in multiple sclerosis patients with more than five years of treatment with stable disease course
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 26 Feb 2016 New trial record